Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • News and press coverage
    • Stock information
    • Governance
    • Documentation

Press releases

24 January 2022

GenSight Biologics reports clinically meaningful vision improvement is maintained 4 years after one-time treatment with LUMEVOQ® gene therapy

18 January 2022

GenSight Biologics Reports Cash Position as of December 31, 2021, and Provides Operational Update

14 December 2021

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial

01 December 2021

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection

30 November 2021

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

22 November 2021

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

17 November 2021

GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment

15 November 2021

GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022

12 November 2021

GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting

10 November 2021

GenSight Biologics Reports Cash Position as of September 30, 2021 and Provides Operational Update

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 17
  • View next 9 articles
© 2022 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page